---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-014242"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:02:29.484414+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q2 net loss $34.8M; identifies ziftomenib Phase 2 dose, $450M cash runway through 2024

## Summary
- Net loss of $34.8M in Q2 2022 vs. $33.7M in Q2 2021; R&D expenses rose to $24.3M.
- Cash, cash equivalents and investments total $450.3M as of June 30, 2022, providing runway through 2024.
- Recommended Phase 2 dose for ziftomenib identified, pending FDA review; additional 18 patients enrolled in KOMET-001 trial.
- Preliminary activity observed in KURRENT-HN trial of tipifarnib + alpelisib; first patient dosed in HRAS overexpression cohort.
- KURRENT-LUNG trial of tipifarnib + osimertinib to initiate in Q3; IND for KO-2806 expected by year-end.

## SEC filing metadata
- accession: 0000950170-22-014242
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017022014242/0000950170-22-014242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017022014242/kura-20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-014242
- JSON: https://secwatch.observer/filing/0000950170-22-014242.json
- Plain text: https://secwatch.observer/filing/0000950170-22-014242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.